Malignant Digestive System Neoplasm

Using univariate analysis, the results showed that underexpression of SMAD4 had a strong relationship with poor OS in pancreatic cancer patients. More specifically, the underexpression of SMAD4 was re… (full text at CIViC)

PMID 26947875 · Shugang et al., 2016 · Open in CIViC

The correlation between FGFR2/SPRY2 and clinicopathologic factors was analyzed by Chi-square to screen the FGFR2/SPRY2-relevant factors. SPRY2 low expression was demonstrated to be significantly assoc… (full text at CIViC)

PMID 28002800 · Xu et al., 2017 · Open in CIViC

Case study of a 46-year old male patient with Peutz-Jeghers Syndrome and pancreatic cancer. A germline STK11 D194E mutation was identified with LOH in the tumor sample. phospho-S6 ribosomal protein st… (full text at CIViC)

PMID 21189378 · Klümpen et al., 2011 · Open in CIViC

In a preclinical study using STK11/LKB1-deficient pancreatic ductal adenocarcinoma (PDAC) cell lines (TB 32047, PANC-1, SUIT2, SU86.86, KPC792) and C57BL/6 orthotopic mouse models (n = 5 per group), t… (full text at CIViC)

PMID 38461159 · Zhang et al., 2024 · Open in CIViC

Patients with metastatic colorectal cancer with STRN-ALK fusion, sporadic microsatellite instability high (MSI-H) and KRAS R164Q received ALK inhibitor ceritinib. After pts received ceritinib perinumb… (full text at CIViC)

PMID 26933125 · Yakirevich et al., 2016 · Open in CIViC

172 patients treated with neoadjuvant concurrent chemoradiotherapy (CCRT) were retrospectively analyzed for expression of thrombospondin 2 (THBS2) using IHC (discovery set with 46 rectal cancer patien… (full text at CIViC)

PMID 26807188 · Lin et al., 2015 · Open in CIViC

This study evaluated genomic biomarkers associated with treatment response and clinical outcomes in patients with locally advanced rectal adenocarcinoma (LARC) treated with neoadjuvant chemoradiation … (full text at CIViC)

PMID 37260182 · Lee et al., 2023 · Open in CIViC

In a single-center observational study of 102 patients with microsatellite stable (MSS) metastatic colon cancer receiving standard treatments, high tumor mutational burden (TMB ≥10 mutations/Mb) was a… (full text at CIViC)

PMID 39639373 · Di Mauro et al., 2024 · Open in CIViC

In a clinical study including 106 patients, over expression of TNC-L is significantly associated with decreased OS by a multivariate analysis (p = 0.0005).

PMID 31463696 · Hagiwara et al., 2020 · Open in CIViC

In an in vitro study, an increased gemcitabine IC50 significantly correlated with increased concentration of TNfnA-D (TNC-L). Resistance reached a platform at 20 ug/ml (p < 0.01).

PMID 20686216 · Gong et al., 2010 · Open in CIViC

The OncoBird framework utilizes data from the open-label, randomized phase III FIRE-3 trial, which involved patients with metastatic colorectal carcinoma who received either cetuximab or bevacizumab i… (full text at CIViC)

PMID 37666855 · Ohnmacht et al., 2023 · Open in CIViC

FFPE tumor samples from 78 patients with colorectal cancer, who had received irinotecan monotherapy were analyzed with a FISH dual-probe. TOP1 gain was nonsignificantly associated with objective respo… (full text at CIViC)

PMID 24256029 · Nygård et al., 2014 · Open in CIViC

498 patients were retrospectively analyzed for topoisomerase 1 expression (IHC). In the subgroup of patients treated with irinotecan (38% of the 498), those patients expressing Topoisomerase I had a b… (full text at CIViC)

PMID 19775480 · Kostopoulos et al., 2009 · Open in CIViC

A prospective study was performed using tumor and normal tissue from 160 colorectal cancer patients undergoing resection. 68 of 160 patients showed tumor p53 mutation, and 18 of 68 cases showed mutati… (full text at CIViC)

PMID 12433709 · Russo et al., 2002 · Open in CIViC

In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival.

PMID 19941080 · Yamasaki et al., 2010 · Open in CIViC

In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.7… (full text at CIViC)

PMID 24740294 · Xu et al., 2014 · Open in CIViC

In a Phase II trial of 25 patients with metastaic gastric cancer, patients received preoperative high dose chemotherapy (HDCT) consisting of etoposide, cisplatin and mitomycin. Patients with greater t… (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

A female patient taking part in a 25 patient gastric cancer trial was diagnosed at age 46, and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score w… (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

In the phase I study of pazopanib and vorinostat in 36 patients with advanced solid tumors, detection of hotspot TP53 mutation was associated with a higher rate of SD ≥6 months/PR, longer median PFS (… (full text at CIViC)

PMID 25669829 · Fu et al., 2015 · Open in CIViC

In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

TP53 mutations were identified in 38/80 colorectal cancer subjects at a Taiwanese hospital. One patient harbored the V143A mutation, and the authors note this is the first identification of V143A in c… (full text at CIViC)

PMID 12795343 · Chang et al., 2003 · Open in CIViC

Analysis of 77 esophageal squamous cell carcinoma tumor and normal samples for germline mutations revealed a rare TP53 V197E variant in a single patient. The V197E mutation is in the DNA-binding domai… (full text at CIViC)

PMID 30833958 · Deng et al., 2019 · Open in CIViC

In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild-type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; h… (full text at CIViC)

PMID 24957073 · Sclafani et al., 2014 · Open in CIViC

Patients with p53 wild type (as defined by low expression and/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 … (full text at CIViC)

PMID 23515910 · Zhang et al., 2013 · Open in CIViC

A male patient taking part in a 25 patient gastric cancer trial was diagnosed at age 50, harbored a TP53 mutation and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric … (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

NTRK1 fusions (one LMNA-NTRK1 and two TPM3-NTRK1) were identified in 2% of Korean colorectal cancer patients (147 patients). TrkA (NTRK1) protein expression was associated with presence of NTRK1 gene … (full text at CIViC)

PMID 26716414 · Park et al., 2016 · Open in CIViC

A female patient, 43 presented with right lower quadrant pain, and was surgically treated for perforated appendicitis including segmental small-bowel resection. Invasive adenocarcinoma stage IIB (pT4a… (full text at CIViC)

PMID 35815302 · Kasi et al., 2022 · Open in CIViC

The TYMS 5' 3TPR germline variant was significantly correlated with lower response to irinotecan plus 5-fluorouracil treatment in colorectal cancer patients. 149 metastatic CRC patients treated with i… (full text at CIViC)

PMID 20628391 · Martinez-Balibrea et al., 2010 · Open in CIViC

Genomic DNA from liver metastases of four different colorectal cancer patients who had previously undergone 5-FU-based adjuvant chemotherapy was evaluated using digital karyotyping. TYMS amplification… (full text at CIViC)

PMID 14970324 · Wang et al., 2004 · Open in CIViC

The TYMS DNA copy number was analyzed in 111 patient samples, divided into two groups: those exposed to 5-FU (n = 62) and those not exposed to 5-FU (n = 49). It was found that the 5-FU exposed group h… (full text at CIViC)

PMID 20727737 · Watson et al., 2010 · Open in CIViC

Reduced TYMS expression by shRNA increased fluorouracil cytotoxicity in HCT-116, HT-29, and SW620 colorectal cancer cells, with approximately 3- to 8-fold enhancement of drug sensitivity.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively).

PMID 22422354 · Shen et al., 2012 · Open in CIViC

shRNA-mediated reduction of UCK2 expression significantly sensitized HCT-116, HT-29, and SW620 colorectal cancer cells to fluorouracil, decreasing IC50 approximately 3- to 6-fold.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

Colorectal cancer cell lines were evaluated for response to the HSP90 inhibitor ganetespib. Correlating cell line-specific IC50s with the corresponding gene expression patterns revealed a possible re… (full text at CIViC)

PMID 25210794 · Landmann et al., 2014 · Open in CIViC

shRNA-mediated reduction of UMPS expression increased resistance to fluorouracil by approximately twofold in HCT-116 and SW620 colorectal cancer cells, as measured by increased IC50.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

Reduction of UNG expression by shRNA significantly sensitized all three colorectal cancer cell lines to fluorouracil. Across the UNG, NME1, and RRM1 experiments, IC50 decreases ranged from approximate… (full text at CIViC)

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

26 colorectal adenocarcinoma samples were run on Affymetrix human Exon 1.0 arrays and a computational method that assessed differential 5' and 3' gene expression for each gene was used to find potenti… (full text at CIViC)

PMID 19737969 · Lin et al., 2009 · Open in CIViC

Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC.

PMID 25973082 · Tsai et al., 2015 · Open in CIViC

Tumor samples from the phase III trial of FOLFOX4
bevacizumab were assessed for VEGF165b and VEGFtotal by immunohistochemistry and scored relative to normal mucosal tissue. Low ratio of VEGF165b/VEG… (full text at CIViC)

PMID 23104894 · Bates et al., 2012 · Open in CIViC

Tumor samples with low ratio of VEGF165b/VEGFtotal treated with bevacizumab compared to placebo showed a trend toward improved PFS (HR 0.49; 95% CI, 0.26 to 0.93). The trend was not significant with p… (full text at CIViC)

PMID 23104894 · Bates et al., 2012 · Open in CIViC

Patients with high baseline plasma VEGF-A levels showed a trend toward improved overall survival (hazard ratio [HR], 0.72; 95% CI, 0.57 to 0.93) versus patients with low VEGF-A levels (HR, 1.01; 95% C… (full text at CIViC)

PMID 22565005 · Van Cutsem et al., 2012 · Open in CIViC

In a clinical trials of 774 patients, patients with high plasma VEGF121 and VEGF110 levels treated with bevacizumab compared to placebo showed a trend toward improved OS (HR 0.72; 95% CI, 0.57 to 0.93… (full text at CIViC)

PMID 22565005 · Van Cutsem et al., 2012 · Open in CIViC

Nude mice were injected with VEGF165b-transfected LS174t colon cancer cells or control LS174t cells and treated with bevacizumab. VEGF165b expressing tumors grew faster than those not expressing VEGF1… (full text at CIViC)

PMID 18349829 · Varey et al., 2008 · Open in CIViC